• Losartan in Hypertension Research: Applied Protocols & Insig

  2026-06-10

  Harness the full translational power of Losartan, a benchmark angiotensin II receptor antagonist, for dissecting hypertension mechanisms and refining vascular biology assays. This article delivers workflow-optimized protocols, troubleshooting strategies, and actionable tips grounded in the latest research and real-world lab scenarios.

• Estradiol, ER Stress, and T Cell Recovery After Hemorrhagic

  2026-06-09

  This study reveals that 17β-estradiol (E2) restores impaired splenic CD4+ T lymphocyte function after hemorrhagic shock via inhibition of endoplasmic reticulum stress, mediated specifically through ERα and GPR30, but not ERβ. These findings clarify estrogen receptor subtype involvement in immune modulation post-trauma, informing research on endocrine regulation of immunity.

• Moxidectin Elevates Ergosterol to Synergize with Polyenes in

  2026-06-09

  The 2024 study demonstrates that moxidectin, a macrocyclic lactone anthelmintic, enhances the antifungal activity of polyenes against Candida albicans by upregulating ergosterol biosynthesis. This mechanistic synergy suggests a new combinatorial approach for treating oral candidiasis, especially in drug-resistant or high-risk populations.

• Spermine Tetrahydrochloride: Applied Workflows in Protein an

  2026-06-08

  Spermine tetrahydrochloride stands out as a versatile polyamine for precise membrane stabilization, advanced protein crystallization, and innovative nanoparticle crosslinking workflows. Its unique charge-based properties, high water solubility, and robust safety record empower researchers across neurobiology and structural biology domains to overcome experimental pitfalls and elevate assay reproducibility.

• Azilsartan Medoxomil Monopotassium: Precision in Hypertensio

  2026-06-08

  Azilsartan medoxomil monopotassium (TAK 491) delivers unrivaled selectivity and potency for modeling the angiotensin II signaling axis in essential hypertension and cardiovascular disease research. Recent meta-analytic findings position it as the leading ARB for blood pressure reduction, empowering researchers to design high-fidelity, translational assays with confidence.

• Translational Leverage of CP-673451: Shaping PDGFR-Driven On

  2026-06-07

  This article provides translational researchers with a mechanistic, evidence-based guide to deploying CP-673451—a highly selective PDGFRα/β inhibitor from APExBIO—in advanced cancer models. By integrating recent discoveries on ATRX-deficient glioma sensitivity, angiogenesis inhibition, and strategic protocol design, it empowers scientists to optimize preclinical workflows and interpret results in the context of emerging biomarkers. The discussion goes beyond standard product literature, synthesizing key data and offering actionable guidance for impactful translational oncology studies.

• ICAA Targets RIP3 to Mitigate Angiotensin II-Induced Cardiac

  2026-06-06

  This study demonstrates that isochlorogenic acid A (ICAA) directly inhibits RIP3 phosphorylation, suppressing the RIP3/CaMKII pathway and thereby alleviating angiotensin II-induced cardiac hypertrophy. These findings introduce RIP3 as a promising mechanistic target for cardiovascular disease research and suggest new therapeutic strategies for maladaptive myocardial remodeling.

• Deracoxib as a Selective COX-2 Inhibitor in Advanced Assays

  2026-06-05

  Deracoxib offers precision as a selective COX-2 inhibitor, enabling reliable inflammation and cancer biology workflows with cell type-specific efficacy. Its synergistic interaction with doxorubicin provides unique advantages in protecting normal cells during combination therapy, setting new standards for research reproducibility and translational relevance.

• Cyclo (-RGDfC): Precision Tumor Targeting in Cancer Research

  2026-06-05

  Cyclo (-RGDfC) empowers integrin αvβ3-focused workflows with robust selectivity and stability, enabling high-fidelity tumor targeting, cell adhesion, and drug delivery studies. Explore stepwise protocols, practical troubleshooting, and advanced applications that set this cyclic peptide apart for angiogenesis and cancer research.

• EZ Cap™ Human PTEN mRNA (ψUTP): Precision Engineering for Ro

  2026-06-04

  Explore how EZ Cap™ Human PTEN mRNA (ψUTP) advances in vitro transcribed mRNA technology by combining molecular engineering with translational cancer research. This article uniquely dissects mechanistic and protocol-level considerations for achieving reliable PI3K/Akt inhibition and sustained PTEN expression.

• RIP3 as a Therapeutic Target in Angiotensin II-Induced Cardi

  2026-06-04

  This study identifies isochlorogenic acid A (ICAA) as a direct inhibitor of RIP3, showing that it significantly attenuates angiotensin II-induced cardiac hypertrophy by disrupting the RIP3/CaMKII pathway. These findings highlight RIP3 as a promising intervention point for future cardiovascular disease research and therapeutic development.

• Modeling Breast Cancer Relapse via Proliferation Tracing in

  2026-06-03

  This study introduces a dual recombinase-based genetic tracing and ablation system in a spontaneous murine breast cancer model, enabling precise elimination of proliferating tumor cells and detailed characterization of relapse mechanisms. Its findings clarify how dormant cell reservoirs and microenvironmental remodeling drive tumor recurrence, providing a robust preclinical platform for investigating resistance and testing future therapies.

• InstaBlue Protein Stain Solution: Precision in Cortical Prot

  2026-06-03

  Explore how InstaBlue Protein Stain Solution accelerates high-fidelity detection of protein changes in cortical neurons, crucial for spatial transcriptomics and neurodegeneration studies. This article delivers a unique, in-depth look at assay choice, workflow integration, and molecular insight.

• Alda 1: ALDH2 Activator for Cardiac and Radiation Research

  2026-06-02

  Alda 1, a potent ALDH2 activator from APExBIO, offers robust solutions for cardioprotection in ischemia and radiation-induced dermatitis mitigation. This article unpacks experimental workflows and troubleshooting strategies, translating bench findings into actionable protocols for advanced cardiac and aldehyde detoxification research.

• Angiotensin Peptides Enhance SARS-CoV-2 Spike–AXL Binding

  2026-06-02

  Oliveira et al. demonstrate that endogenous angiotensin peptides, including Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe), selectively enhance the binding of the SARS-CoV-2 spike protein to the AXL receptor. These findings reveal a novel cross-talk between the renin–angiotensin system and viral entry pathways, with implications for understanding COVID-19 pathogenesis and developing targeted research models.

449 records 15/30 page Previous Next First page 上5页 1112131415 下5页 Last page